We can improve the general health outcomes of people with diabetes and related complications by identifying and treating the disease as soon as possible, and the findings of our study establish both the need and proof to reconsider the threshold to screen patients for NAFLD who do not have adequate glycemic control, and to pay more attention to ALT as its derangement indicates the possible future onset/progression of NASH. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.